News

Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products

Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer

Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft

Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery

Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Cerapedics Announces Canadian Approval of its next-generation bone graft

Canada will be the first commercial market to launch i-FACTOR®+ Matrix

Cerapedics Announces FDA approval of an IDE supplement

The IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.

Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

Data published in The Spine Journal show elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rate with i-FACTOR bone graft compared to allograft

Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data

i-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery